Literature DB >> 18282203

Probing attentional dysfunctions in schizophrenia: Startle modification during a continuous performance test.

Erin A Hazlett1, Michael E Dawson, Anne M Schell, Keith H Nuechterlein.   

Abstract

Startle eyeblink modification was measured in 20 relatively asymptomatic medicated schizophrenia outpatients and 18 matched controls in order to test for deficits in early and later stages of attentional processing during a memory-load version of the Continuous Performance Test. Participants viewed a series of digits and pressed a button after the digit 7 of each 3-7 sequence. On some trials, a startling noise burst was presented either 120 or 1200 ms following cues that a response might be needed soon (the digit 3) and also following noncues. Controls showed greater startle inhibition at 120 ms following cue than noncue prepulses, whereas patients showed equal inhibition to both, suggesting a deficiency in allocation of controlled attentional resources in early stages of processing. The patients, however, did show large startle inhibition at 120 ms when a distracting stimulus accompanied the task-relevant cue, unlike the controls, who ignored the distracting stimulus. In contrast, both groups showed equal startle inhibition 1200 ms following cue and noncue prepulses, indicating that later modality-specific attention processes are not impaired in patients during this paradigm. Both groups also showed equal inhibition at 120 ms during passively attended prepulses, suggesting that automatic attentional processes were not impaired in these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18282203     DOI: 10.1111/j.1469-8986.2008.00653.x

Source DB:  PubMed          Journal:  Psychophysiology        ISSN: 0048-5772            Impact factor:   4.016


  7 in total

1.  Frontal-striatal-thalamic mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating.

Authors:  Erin A Hazlett; Monte S Buchsbaum; Jing Zhang; Randall E Newmark; Cathryn F Glanton; Yuliya Zelmanova; M Mehmet Haznedar; King-Wai Chu; Igor Nenadic; Eileen M Kemether; Cheuk Y Tang; Antonia S New; Larry J Siever
Journal:  Neuroimage       Date:  2008-07-11       Impact factor: 6.556

2.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

3.  Associations between TCF4 gene polymorphism and cognitive functions in schizophrenia patients and healthy controls.

Authors:  Xianghua Zhu; Huang Gu; Zhen Liu; Zhansheng Xu; Xiongying Chen; Xiaochen Sun; Jinguo Zhai; Qiumei Zhang; Min Chen; Keqin Wang; Xiaoxiang Deng; Feng Ji; Chuanxin Liu; Jun Li; Qi Dong; Chuansheng Chen
Journal:  Neuropsychopharmacology       Date:  2012-11-09       Impact factor: 7.853

4.  Lack of relationship between acoustic startle and cognitive variables in schizophrenia and control subjects.

Authors:  Wendy Hasenkamp; Mary Kelley; Glenn Egan; Amanda Green; Lisette Wilcox; William Boshoven; Barbara Lewison; Erica Duncan
Journal:  Psychiatry Res       Date:  2011-03-11       Impact factor: 3.222

5.  Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia.

Authors:  Taryn G Moss; Kristi A Sacco; Taryn M Allen; Andrea H Weinberger; Jennifer C Vessicchio; Tony P George
Journal:  Drug Alcohol Depend       Date:  2009-05-17       Impact factor: 4.492

6.  Simultaneous EMG-fMRI during startle inhibition in monosymptomatic enuresis--an exploratory study.

Authors:  Sebastian Schulz-Juergensen; David Wunberg; Stephan Wolff; Paul Eggert; Michael Siniatchkin
Journal:  Eur J Pediatr       Date:  2012-09-18       Impact factor: 3.183

7.  Effects of Stimulus-Driven and Goal-Directed Attention on Prepulse Inhibition of Brain Oscillations.

Authors:  Agnès Annic; Jean-Louis Bourriez; Arnaud Delval; Perrine Bocquillon; Claire Trubert; Philippe Derambure; Kathy Dujardin
Journal:  Front Hum Neurosci       Date:  2016-07-29       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.